Shanghai Shen Lian Biomedical Corp. (688098.SH) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenCNY 8.00

From 52W high−19.03%

Volume3.60M

Market capCNY 3.29B

P/E (TTM)−160.3x

P/S (TTM)12.6x

Div yield—

Key dataSep 18, 2026

Open

CNY 8.00

From 52W high

−19.03%

Volume

3.60M

Market cap

CNY 3.29B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

71.5x

P/E (TTM)

−160.3x

RSI (14)

53.0

MomentumView details →

1D Return

−3.03%

YTD Return

—

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

−160.3x

EV/EBITDA

71.5x

EV/Sales

12.4x

P/S (TTM)

12.6x

P/B (TTM)

2.4x

ProfitabilityView details →

Gross Margin

57.71%

Net Margin

−7.06%

EBITDA Margin

17.33%

ROE (TTM)

−1.38%

ROA (TTM)

−1.26%

Asset Turnover

0.18x

GrowthView details →

Revenue YoY

−7.47%

EPS YoY

+57.21%

FCF YoY

—

Revenue CAGR 3Y

−4.27%

EPS CAGR 3Y

+54.55%

EBITDA YoY

—

MomentumView details →

1D Return

−3.03%

YTD Return

—

1Y Return

—

RSI (14)

53.0

vs 50D SMA

−0.28%

vs 200D SMA

—

Capital & dividendView details →

Debt/Equity

0.01x

Current Ratio

4.00x

Quick Ratio

3.11x

Div Yield

—

Div Rate

—

Div Growth 1Y

−56.25%

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

272.12M

Net Income (TTM)

−19.21M

Op. CF (TTM)

21.56M

Latest newsMore news →

Shenlian Biotech's controlled subsidiary Shizhiyuan announced that its biologic drug UB-221 injection met the primary endpoint in a Phase II clinical trial for chronic spontaneous urticaria, with positive topline results in 145 patients.6h ago

Shenlian Biotechnology signed a supplementary contract with the Lanzhou Veterinary Research Institute of the Chinese Academy of Agricultural Sciences and other units to add SAT1-type foot-and-mouth disease antigens for pigs and cattle to their existing multi-valent vaccine co-development contract.4d ago

Similar companies

Laekna, Inc.02105.HK 之江生物688317.SH Arcus Biosciences, Inc.RCUS Veracyte, Inc.VCYT Dyne Therapeutics, Inc.DYN Viking Therapeutics, Inc.VKTX Find similar companies →

Latest newsMore news →

Shenlian Biotech's controlled subsidiary Shizhiyuan announced that its biologic drug UB-221 injection met the primary endpoint in a Phase II clinical trial for chronic spontaneous urticaria, with positive topline results in 145 patients.6h ago Shenlian Biotechnology signed a supplementary contract with the Lanzhou Veterinary Research Institute of the Chinese Academy of Agricultural Sciences and other units to add SAT1-type foot-and-mouth disease antigens for pigs and cattle to their existing multi-valent vaccine co-development contract.4d ago